Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. has updated its FY26 earnings per share (EPS) estimates positively, reflecting an upward adjustment to $(3.76) from a previous $(4.17), indicating improved financial projections and a growing confidence in its market potential. The anticipated approval of the MyoVista device, alongside the rollout of the MyoVista Insights cloud platform and expected FDA approval of its diagnostic algorithm by the first half of 2026, positions the company well for significant growth in the healthcare sector. With a newly established price target of $9.20, which suggests substantial upside potential, HeartSciences is strategically poised to tap into a large market opportunity in cardiac diagnostics.

Bears say

HeartSciences Inc. is facing significant financial challenges, as evidenced by a sharp reduction in projected FY2026 revenue estimates, which have been lowered from $1.2 million to $0.1 million due to FDA-related delays. Moreover, the company is encountering multiple risks that could adversely affect its financial performance, including balance sheet and liquidity issues, potential failure of product candidates in clinical trials, and challenges in securing regulatory approvals and reimbursement. The overall outlook is further complicated by competition and changing macroeconomic conditions, which could diminish investor sentiment towards healthcare stocks, thereby impacting the company's financial viability.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.